title: Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease.
abstract: BACKGROUND
  Expression and activity of the fibroblast growth factor (FGF) 21 hormone-like protein are associated with development of several metabolic disorders. This study was designed to investigate whether serum FGF21 level was also associated with the metabolic syndrome-related cardiovascular disease, atherosclerosis, and its clinical features in a Chinese cohort.
  
  
  METHODS
  Two-hundred-and-fifty-three subjects visiting the Cardiology Department (Sixth People's Hospital affiliated to Shanghai JiaoTong University) were examined by coronary arteriography (to diagnose coronary artery disease (CAD)) and hepatic ultrasonography (to diagnose non-alcoholic fatty liver disease (NAFLD)). Serum FGF21 level was measured by enzyme-linked immunosorbent assay and analyzed for correlation to subject and clinical characteristics. The independent factors of CAD were determined by multivariate logistic regression analysis.
  
  
  RESULTS
  Subjects with NAFLD showed significantly higher serum FGF21 than those without NAFLD (388.0 pg/mL (253.0-655.4) vs. 273.3 pg/mL (164.9-383.7), P < 0.01). Subjects with CAD showed significantly higher serum FGF21, regardless of NAFLD diagnosis (P < 0.05). Serum FGF21 level significantly elevated with the increasing number of metabolic disorders (P for trend < 0.01). After adjustment of age, sex, and BMI, FGF21 was positively correlated with total cholesterol (P < 0.05) and triglyceride (P < 0.01). FGF21 was identified as an independent factor of CAD (odds ratio = 2.984, 95% confidence interval: 1.014-8.786, P < 0.05).
  
  
  CONCLUSIONS
  Increased level of serum FGF21 is associated with NAFLD, metabolic disorders and CAD.
authors: Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Diabetes Institute, Shanghai, China. byq522@163.com.
authors: Yun
authors: Y
authors: Shen
authors: Xiaojing
authors: X
authors: Ma
authors: Jian
authors: J
authors: Zhou
authors: Xiaoping
authors: X
authors: Pan
authors: Yaping
authors: Y
authors: Hao
authors: Mi
authors: M
authors: Zhou
authors: Zhigang
authors: Z
authors: Lu
authors: Meifang
authors: M
authors: Gao
authors: Yuqian
authors: Y
authors: Bao
authors: Weiping
authors: W
authors: Jia
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D002681:China / Q000453:epidemiology; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood* / Q000000981:diagnostic imaging / Q000208:ethnology; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005234:Fatty Liver / Q000097:blood / Q000000981:diagnostic imaging / Q000208:ethnology; D005260:Female; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D016015:Logistic Models; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000208:ethnology; D008875:Middle Aged; D015999:Multivariate Analysis; D065626:Non-alcoholic Fatty Liver Disease; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors; D014463:Ultrasonography
chemical_list: D015415:Biomarkers; C414620:fibroblast growth factor 21; D005346:Fibroblast Growth Factors
references: Gynecol Endocrinol. 2010 Nov;26(11):819-26
references: 20486877
references: Zhonghua Gan Zang Bing Za Zhi. 2010 Mar;18(3):163-6
references: 20698076
references: Clin Endocrinol (Oxf). 2009 Sep;71(3):369-75
references: 19702724
references: Clin Endocrinol (Oxf). 2014 Jan;80(1):57-64
references: 23278761
references: Endocr Res. 2011;36(4):142-8
references: 21973233
references: Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):21-5
references: 23227282
references: Diabetes Res Clin Pract. 2012 May;96(2):196-203
references: 22293928
references: J Hepatol. 2010 Nov;53(5):934-40
references: 20675007
references: Metabolism. 2010 Jan;59(1):33-7
references: 19699495
references: J Clin Endocrinol Metab. 2012 Jun;97(6):2143-50
references: 22438225
references: Physiol Res. 2009;58(1):1-7
references: 19331512
references: J Clin Endocrinol Metab. 2012 Apr;97(4):1375-82
references: 22344195
references: J Hepatol. 2013 Mar;58(3):557-63
references: 23142063
references: J Clin Endocrinol Metab. 2011 Feb;96(2):E351-5
references: 21123446
references: J Clin Endocrinol Metab. 2009 Jun;94(6):2151-6
references: 19318452
references: Chin Med J (Engl). 2010 Dec;123(23):3417-21
references: 22166524
references: Cardiovasc Diabetol. 2012 Oct 01;11:117
references: 23020992
references: Radiol Clin North Am. 1968 Dec;6(3):467-92
references: 4881403
references: JAMA. 1999 Oct 6;282(13):1247-53
references: 10517427
references: Endocrinology. 2008 Dec;149(12):6018-27
references: 18687777
references: Front Med. 2013 Mar;7(1):25-30
references: 23358894
references: Eur J Endocrinol. 2012 Sep;167(3):301-9
references: 22740503
references: Zhonghua Xin Xue Guan Bing Za Zhi. 2007 May;35(5):390-419
references: 17711682
references: Cardiovasc Diabetol. 2012 Jun 07;11:61
references: 22676459
references: Biochim Biophys Acta. 2000 Jun 21;1492(1):203-6
references: 10858549
references: PLoS One. 2010 Dec 29;5(12):e15534
references: 21206918